Dientsbier Z, Foltýnová V, Hermanská Z, Chytrý P, Maríková E
Ustav biofyziky a nukleární medicíny 1. lékarské fakulty Univerzity Karlovy, Praha.
Sb Lek. 1991 May;93(3-4):84-94.
The authors investigate within the framework of a multicentre, randomized and stratified investigation the influence of non-specific BCG immunotherapy in adult patients with Hodgkin's disease. The thus created data base was processed according to the Protocol of a prospective study. Supplementary BCG treatment was compared in a group of 112 patients with the fate of 114 patients in a control group without immunotherapy. Although the mean period of complete remission in the group of vaccinated patients regardless of the clinical stage of the disease was 94 months and in the control group 74 months, the difference was not statistically significant. The five-year survival was 93% in vaccinated patients and 91% in the control group. The probability of 10-year survival does not differ substantially in vaccinated patients (88%) and in non-vaccinated patients (85%). There was no difference in the work capacity of patients in the two groups. Immunotherapy was not selected, when testing prognostic factors by Cox' regression analysis, into any of the prognostically favourable models.
作者们在一项多中心、随机且分层的研究框架内，调查了非特异性卡介苗免疫疗法对成年霍奇金病患者的影响。据此建立的数据库按照一项前瞻性研究的方案进行处理。在一组112例患者中比较了补充卡介苗治疗与114例未接受免疫疗法的对照组患者的转归。尽管无论疾病临床分期如何，接种疫苗组患者的平均完全缓解期为94个月，而对照组为74个月，但差异无统计学意义。接种疫苗患者的五年生存率为93%，对照组为91%。接种疫苗患者（88%）和未接种疫苗患者（85%）的十年生存概率无显著差异。两组患者的工作能力无差异。在通过Cox回归分析测试预后因素时，免疫疗法未被纳入任何预后良好的模型。
